Navigation Links
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Date:6/7/2012

ogy practice groups, and health maintenance organizations in the United States, Canada, Puerto Rico, Australia, and Ireland.  At those sites and their satellites, more than 5000 physicians, nurses, and other medical professionals conduct NSABP treatment and prevention trials.

In addition to Dr. Jacobs, another member of the SAB, an oncologist specializing in comparative effectiveness studies of targeted therapies and biomarkers, mathematical and statistical prognostic and predictive models, and advanced methods of evidence synthesis in support of clinical practice guidelines, will attend the meeting.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express we
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Generex Secures Commitments for $3.6M Capital Raise
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... and RARITAN, N.J. , May ... open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial ... human anti-CD38 monoclonal antibody – achieved an overall ... 20.8-38.9), as assessed by an independent review committee, ... ORR was consistent among the pre-specified subgroups based ...
(Date:5/29/2015)... Norway , May 29, 2015 ... biopharmaceutical company, today announces that an abstract on the ... molecule inhibitor of the Axl receptor tyrosine kinase, and ... at BerGenBio, has been published in conjunction with the ... in Chicago , May 29 - ...
(Date:5/29/2015)... Market Publishers Ltd and Shanghai ... partnership agreement for quality market research promotion on ... sell research reports worked out by Chem-Report. , ... upon the agreement: “Chem-Report is a Chinese company ... chemical markets on global and country levels. The ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... Cynvec LLC, a privately held biotechnology company focused ... ability of the sindbis viral vector, today announced that ... a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy ... on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks, presentation ...
... Pharmaceuticals, a pioneer in the development of novel products ... disease, announced that it has promoted F. Stephen Laroux, ... inflammatory diseases, effective immediately. Dr. Laroux joined the company ... team of Cequent researchers developing drug candidates using Cequent,s ...
... LLC announced today that it has issued an Executive Informational ... full 56-page report can be found at www.crystalra.com ... Company") is a development-stage biotechnology company focused on the discovery ... inactive precursor of a drug that is converted into its ...
Cached Biology Technology:Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 2Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc. 3
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... catch more than a cold from certain viruses. Some ... their insides to soup - without harming beneficial insects ... environmentally friendly means of biological crop protection worldwide. The ... has been controlled in European orchards for years with ...
... of the worlds worst pollution problems of the 1970s and ... Europe and North America. In Wales, more than 12,000 ... stream insects and river birds such as the dipper. ... Europe to clean up acid pollutants from power generation and ...
... States participating in the GMES Programme approved the transition ... Component Programme. Oversubscription of the programme by the ... with oversubscription to phase 2 of 116%, giving a ... the programme will allow ESA to confirm the development ...
Cached Biology News:Surprise in the organic orchard -- a healthier worm in the apple 2Recovery from acid rain 'much slower than expected' 2
... Rabbit polyclonal to MLF1 Interacting ... for all tested applications). ... corresponding to amino acids 73-83 of ... Entrez Gene ID: 359815 ...
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
Biology Products: